Clinical Trials
12 trialsNCT02998476 2025-08-22
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
Phase 2 Completed
NCT03039114 2025-08-21
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
Phase 1 Completed
NCT03424122 2025-08-21
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Phase 1 Completed
NCT03144674 2025-07-11
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Incyte Corporation
Phase 2 Completed
NCT03235544 2025-03-18
(CITADEL-205)
Incyte Corporation
Phase 2 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT04774068 2025-01-17
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04434937 2024-10-23
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
Incyte Corporation
Phase 2 Completed
NCT04298879 2024-06-05
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT03314922 2023-08-14
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Incyte Corporation
Phase 1 Completed
NCT03688152 2020-11-10
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Incyte Corporation
Phase 1 Completed